Neurocrine Biosciences Announces Positive Results in Daisy PETAL Study PHASE II STUDY MEETS ALL EFFICACY ENDPOINTS
SAN DIEGO, May 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq:NBIX - News) today announced statistically significant and clinically meaningful top-line efficacy results from its Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.
“The Daisy PETAL study was successful, all primary and secondary efficacy endpoints were met, and provided exactly the information we need to move this program forward,” said Chris O’Brien, M.D., Chief Medical Officer at Neurocrine. “We now have confirmation that the daily scales for menstrual and non-menstrual pelvic pain, developed with extensive input from the FDA and patients, function well in a clinical trial setting. These daily endpoints reflect the way women with endometriosis experience their symptoms and also demonstrate improvement with elagolix.”
Market Data 
Markets 
AI
